Pressmeddelande

BioStock: Abliva’s CEO comments on the proposed capital raise

Cision Publicerad: 29 Feb 09:46

Abliva’s 2023 Year-End report focuses on the successful enrolment in December for Wave 1 of the phase II 'FALCON' study with lead candidate KL1333. Other key milestones include initiating dosing and receiving Fast Track Designation for the programme. BioStock contacted Abliva’s CEO Ellen Donnelly to learn more about the most impactful milestones achieved during the quarter and the recently announced rights issue that aims to support ongoing activities and provide additional runway.

Read the interview with Ellen Donnelly at biostock.se:

Abliva’s CEO comments on the proposed capital raise - BioStock

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

Nyheter om Abliva

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!